Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium
Viruses · 2023
DOI: 10.3390/v15030747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mari Numata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Jewish Health, Denver, CO 80206, USA. Hauptthemen laut MEDLINE: Enterovirus Infections, Pulmonary Surfactants, Picornaviridae Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Rhinoviruses (RVs) are major instigators of acute exacerbations of asthma, COPD, and other respiratory diseases. RVs are categorized into three species (RV-A, RV-B, and RV-C), which comprise more than 160 serotypes, making it difficult to develop an effective vaccine. Currently, no effective treatment for RV infection is available. Pulmonary surfactant is an extracellular complex of lipids and proteins that plays a central role in regulating innate immunity in the lung. The minor pulmonary surfactant lipids, palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI), are potent regulators of inflammatory processes and exert antiviral activity against respiratory syncytial virus (RSV) and influenza A viruses (IAV). In the current study, we examined the potencies of POPG and PI against rhinovirus A16 (RV-A16) in primary human airway epithelial cells (AECs) differentiated at an air–liquid interface (ALI). After AECs were infected with RV-A16, PI reduced the viral RNA copy number by 70% and downregulated (55–75%) the expression of antiviral (MDA5, IRF7, and IFN-lambda) and CXCL11 chemokine genes. In contrast, POPG only slightly decreased MDA5 (24%) and IRF7 (11%) gene expression but did not inhibit IFN-lambda gene expression or RV-A16 replication in AECs. However, both POPG and PI inhibited (50–80%) IL6 gene expression and protein secretion and CXCL11 protein secretion. PI treatment dramatically attenuated global gene expression changes induced by RV-A16 infection alone in AECs. The observed inhibitory effects were indirect and resulted mainly from the inhibition of virus replication. Cell-type enrichment analysis of viral-regulated genes opposed by PI treatment revealed the PI-inhibited viral induction of goblet cell metaplasia and the virus-induced downregulation of ciliated, club, and ionocyte cell types. Notably, the PI treatment also altered the ability of RV-A16 to regulate the expression of some phosphatidylinositol 4-kinase (PI4K); acyl-CoA-binding, domain-containing (ACBD); and low-density lipoprotein receptor (LDLR) genes that play critical roles in the formation and functioning of replication organelles (ROs) required for RV replication in host cells. These data suggest PI can be used as a potent, non-toxic, antiviral agent for RV infection prophylaxis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, National Jewish Health, Denver, CO 80206, USA.
- Center for Genes, Environment and Health, National Jewish Health, Denver, CO 80206, USA.
- Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
- Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA.
- Section of Pediatric Pulmonary & Sleep Medicine, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO 80045, USA.
ORCID-Profile: Yury A Bochkov, Riley A Cooney
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- Clinical innovator Award Program
- Flight Attendant Medical Research Institute, Inc.
- National Emphysema Foundation
Zitieren
APA
Numata, M., Sajuthi, S., Bochkov, Y. A., Loeffler, J., Everman, J., Vladar, E. K., Cooney, R. A., Reinhardt, R. L., Liu, A. H., Seibold, M. A., & Voelker, D. R. (2023). Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium. Viruses. https://doi.org/10.3390/v15030747
Vancouver
Numata M, Sajuthi S, Bochkov YA, Loeffler J, Everman J, Vladar EK, et al. Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium. Viruses. 2023. doi:10.3390/v15030747
BibTeX
@article{Numata2023,
author = {Numata, Mari and Sajuthi, Satria and Bochkov, Yury A and Loeffler, Jessica and Everman, Jamie and Vladar, Eszter K and Cooney, Riley A and Reinhardt, Richard Lee and Liu, Andrew H and Seibold, Max A and Voelker, Dennis R},
title = {Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15030747}
}
EUVIMED